ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Wednesday, November 13, 2019

9:00AM-10:30AM
Abstract Number: 2869
Access to Care and Diagnostic Delays in Juvenile Dermatomyositis
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)
9:00AM-10:30AM
Abstract Number: 2871
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)
9:00AM-10:30AM
Abstract Number: 2885
An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)
9:00AM-10:30AM
Abstract Number: 2873
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)
9:00AM-10:30AM
Abstract Number: 2865
Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)
9:00AM-10:30AM
Abstract Number: 2868
Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)
9:00AM-10:30AM
Abstract Number: 2887
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)
9:00AM-10:30AM
Abstract Number: 2859
Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA
6W012: RA – Etiology & Pathogenesis II (2858–2863)
9:00AM-10:30AM
Abstract Number: 2884
Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years
6W013: SLE – Clinical VI: Epidemiology, Diagnosis, & Outcomes (2882–2887)
9:00AM-10:30AM
Abstract Number: 2874
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)
9:00AM-10:30AM
Abstract Number: 2891
Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs
6W017: Health Services Research II: Health Economics (2888–2893)
9:00AM-10:30AM
Abstract Number: 2888
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural Language Processing Tool for Complex Prescription Instructions
6W017: Health Services Research II: Health Economics (2888–2893)
9:00AM-10:30AM
Abstract Number: 2881
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
6W014: Spondyloarthritis Including Psoriatic Arthritis – Clinical VII: Psoriatic Arthritis Treatment (2876–2881)
9:00AM-10:30AM
Abstract Number: 2875
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
6W011: RA – Diagnosis, Manifestations, & Outcomes V: Treatment (2870–2875)
9:00AM-10:30AM
Abstract Number: 2864
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
6W010: Pediatric Rheumatology – Clinical III: Juvenile SLE & Dermatomyositis (2864–2869)
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences